Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor

Pharmacotherapy

Volumn 18, Issue 5, 1998, Pages 1129-1132

  Piecoro, Lance T ^a   Wermeling, Daniel P ^a,c   Schmitt, Frederick A ^b   Ashford, J Wesson ^b  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Department of Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; BELLADONNA ALKALOID; BENAZEPRIL; BENZATROPINE; BROMOCRIPTINE; CHOLINESTERASE INHIBITOR; CONJUGATED ESTROGEN; DICYCLOVERINE; DIPHENHYDRAMINE; DOXEPIN; ESTRADIOL; GLYCOPYRRONIUM BROMIDE; HYOSCYAMINE; LEVODOPA; LOPERAMIDE; MEDROXYPROGESTERONE; MELATONIN; METRIFONATE; MULTIVITAMIN; MUSCARINIC RECEPTOR BLOCKING AGENT; NAPROXEN; OXYBUTYNIN; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL; UNINDEXED DRUG; VERAPAMIL;

ADULT; ALLERGY; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; CHOLINESTERASE INHIBITION; DEGENERATIVE DISEASE; DEPRESSION; DIARRHEA; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; NEUROLOGIC DISEASE; PARKINSON DISEASE; SEIZURE; TREATMENT INDICATION; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; ATROPINE; CHOLINESTERASE INHIBITORS; DOXEPIN; DRUG INTERACTIONS; FEMALE; HUMANS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; SEIZURES; TRICHLORFON;

EID: 0031684379     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
2. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977;1:189.
3. Sims NR, Bowen DM, Allen SJ, et al. Presynaptic cholinergic dysfunction in patients with dementia, J Neurpchem 1983;40(2):503-9.
4. Whitehouse PJ, Clark AW, Price DL, Struble RG, DeLong MR, Coyle JT. Alzheimer's disease (AD): loss of cholinergic neurons in the nucleus basalis. J Neuropathol Exp Neurol 1981;40:323.
5. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974;30:113-21.
6. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebocontrolled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-9.
7. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-9.
8. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271(13):985-91.
9. Nightingale SL. Donepezil approved for treatment of Alzheimer disease. JAMA 1997;277(1):10.
10. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Dev Res 1990;19:425-34.
11. Bieber F, Mas J, Orazem J, Gulanski B. Results of a dose finding study with metrifonate in patients with Alzheimer's disease (AD) [abstr]. Presented at the 4th international symposium on advances in Alzheimer therapy, Nice, France, April 10-14, 1996.
12. Ashford JW, Schmitt FS, Wermeling DP, Bieber F, Orazem J, Gulanski B. Advantages of the "time-index" method for measurement of Alzheimer dementia: assessment of metrifonate benefit. In: Becker R, Giacobini E, eds. Alzheimer disease from molecular biology to therapy, 1st ed. Boston: Birkhauser, 1996:431-4.
13. Anonymous. Levsinex timecaps. In: Physicians' desk reference, 49th ed. Montvale, NJ: Medical Economics, 1995.
14. Anonymous. Zonalon cream. In: Physicians' desk reference, 49th ed. Montvale, NJ: Medical Economics, 1995.
15. Markowitz JC, Brown RP. Seizures with neuroleptics and antidepressants. Gen Hosp Psychiatry 1987;9:135-41.
16. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993;34(3):453-68.
17. Lühdorf K, Jensen LK, Plesner AM. Epilepsy in the elderly: incidence, social function, and disability. Epilepsia 1986;27(2):135-41.
18. Sander JWAS, Hart YM, Johnson AL, Shorvon SD. National general practice study of epilepsy: newly diagnosed epileptic seizures in a general population. Lancet 1990;336:1267-71.
19. Forsgren L, Bucht G, Eriksson S, Bergmark L. Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. Epilepsia 1996;37(3):224-9.
20. Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA. Dementia and adult-onset unprovoked seizures. Neurology 1996;46:727-30.
21. Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patient's with Alzheimer's disease. Neurology 1986;36:1226-30.
22. Volicer L, Smith S, Volicer BJ. Effect of seizures on progression of dementia of the Alzheimer type. Dementia 1995;6:258-63.
23. Taylor P. Anticholinesterase agents. In: Gilman AF, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: Pergamon Press, 1990:131-49.
24. Delgado-Escueta AV, Ward AA, Woodbury DM, Porter RJ. New wave of research in the epilepsies. In: Delgado-Escueta AV, Ward AA, Woodbury DM, Porter RJ, eds. Advances in neurology. Vol. 44. Basic mechanisms of the epilpsies -molecular and cellular approaches. New York: Raven Press, 1986:26.
25. Sidell FR. Clinical effects of organophosphorus cholinesterase inhibitors. J Appl Toxicol 1994;14(2):111-13.
26. Lebert F, Hasenbroekx C, Pasquier F, Petit H. Convulsive effects of tacrine. Lancet 1996;347:1339-40.
27. Mattson MP. Calcium and neuronal injury in Alzheimer's disease. Contributions of beta-amyloid precursor protein mismetabloism, free radicals, and metabolic compromise. Ann NY Acad Sci 1994;747:50-76.
28. Anonymous. Robinul. In: Physicians' desk reference, 49th ed. Montvale, NJ: Medical Economics, 1995.